April 2018 in “Journal of Investigative Dermatology” BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.
19 citations
,
December 2008 in “Arthritis Care & Research” The decision board effectively helps lupus nephritis patients in Brazil choose treatments by clearly presenting options and side effects.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Rituximab can cause skin issues, but baricitinib may help improve them.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
15 citations
,
February 2024 in “Journal of Dermatological Treatment” Dupilumab may help treat alopecia areata without needing high IgE levels.
14 citations
,
January 2017 in “Dermatology Online Journal” Adalimumab can cause hair loss and scalp issues in some psoriasis patients.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
February 2026 in “Indian Journal of Skin Allergy” Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
July 2024 in “Journal of Investigative Dermatology” ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.
May 2024 in “Archives of Dermatological Research” TAT-GILZ peptide promotes hair growth by boosting stem cell activity.
Controlling Tslp can improve health in AEC syndrome patients.
2 citations
,
October 2022 in “Current Allergy and Asthma Reports” Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
20 citations
,
November 2017 in “JAAD case reports” Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
1 citations
,
October 2015 in “The American journal of gastroenterology” Stopping infliximab and using strong topical steroids can regrow hair lost due to psoriasiform alopecia.
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
October 2021 in “European journal of cancer” Repeated biopsies are crucial for managing lupus panniculitis when initial treatments fail.
2 citations
,
September 2021 in “Curēus” Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
March 2010 in “Anti-inflammatory & anti-allergy agents in medicinal chemistry” Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.
3 citations
,
May 2020 in “JAAD Case Reports” Two patients with psoriasis grew extra hair after using certain psoriasis medications.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
37 citations
,
October 2014 in “JAMA dermatology” A woman with severe hair loss was successfully treated with the drug adalimumab.
2 citations
,
November 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.
2 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.
4 citations
,
May 2018 in “Journal of Neuro-Ophthalmology” New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.